261 related articles for article (PubMed ID: 30973022)
1. The impact of adding hp-hMG in r-FSH started GnRH antagonist cycles on ART outcome.
Kan O; Simsir C; Atabekoglu CS; Sonmezer M
Gynecol Endocrinol; 2019 Oct; 35(10):869-872. PubMed ID: 30973022
[TBL] [Abstract][Full Text] [Related]
2. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels.
Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM
Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817
[TBL] [Abstract][Full Text] [Related]
3. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
4. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
5. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study.
Bosch E; Vidal C; Labarta E; Simon C; Remohi J; Pellicer A
Hum Reprod; 2008 Oct; 23(10):2346-51. PubMed ID: 18583332
[TBL] [Abstract][Full Text] [Related]
6. Comparison between stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF with GnRH antagonist protocol.
Shavit T; Shalom-Paz E; Samara N; Aslih N; Michaeli M; Ellenbogen A
Gynecol Endocrinol; 2016 Aug; 32(8):629-633. PubMed ID: 26939574
[TBL] [Abstract][Full Text] [Related]
7. A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
Chen MJ; Yi YC; Guu HF; Chen YF; Kung HF; Chang JC; Chuan ST; Chen LY
Front Endocrinol (Lausanne); 2022; 13():931756. PubMed ID: 36046790
[TBL] [Abstract][Full Text] [Related]
8. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.
Agrawal R; Conway GS; Engmann L; Bekir JS; Jacobs HS
Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704
[TBL] [Abstract][Full Text] [Related]
9. Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction.
Souza PMG; Carvalho BR; Nakagawa HM; Rassi TRE; Barbosa ACP; Silva AA
JBRA Assist Reprod; 2017 Jun; 21(2):67-69. PubMed ID: 28609269
[TBL] [Abstract][Full Text] [Related]
10. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.
Moro F; Scarinci E; Palla C; Romani F; Familiari A; Tropea A; Leoncini E; Lanzone A; Apa R
Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971
[TBL] [Abstract][Full Text] [Related]
11. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
[TBL] [Abstract][Full Text] [Related]
12. The impact of LH-containing gonadotropin stimulation on euploidy rates in preimplantation embryos: antagonist cycles.
Weghofer A; Munné S; Brannath W; Chen S; Barad D; Cohen J; Gleicher N
Fertil Steril; 2009 Sep; 92(3):937-942. PubMed ID: 18774557
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
14. Adding human menopausal gonadotrophin to antagonist protocols - is there a benefit?
Martin-Johnston M; Beltsos AN; Grotjan HE; Uhler ML
Reprod Biomed Online; 2007 Aug; 15(2):161-8. PubMed ID: 17697491
[TBL] [Abstract][Full Text] [Related]
15. Recombinant follicular stimulating hormone plus recombinant luteinizing hormone versus human menopausal gonadotropins- does the source of LH bioactivity affect ovarian stimulation outcome?
Kirshenbaum M; Gil O; Haas J; Nahum R; Zilberberg E; Lebovitz O; Orvieto R
Reprod Biol Endocrinol; 2021 Dec; 19(1):182. PubMed ID: 34886872
[TBL] [Abstract][Full Text] [Related]
16. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
Polyzos NP; De Vos M; Corona R; Vloeberghs V; Ortega-Hrepich C; Stoop D; Tournaye H
Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
[TBL] [Abstract][Full Text] [Related]
17. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
18. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
19. Do the suppression criteria in GnRH-a cycles predict in vitro fertilization outcome?
Senöz S; Gülekli B; Turhan NO; Ozakşit G; Odabaşi AR; Oral H; Ozcan U; Gökmen O
Gynecol Endocrinol; 1995 Jun; 9(2):91-6. PubMed ID: 7502695
[TBL] [Abstract][Full Text] [Related]
20. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
